SAN.PA
$76.51
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Recent News
Is There Now An Opportunity In Sanofi (ENXTPA:SAN) After A 25% Share Price Slide?
Investors may be wondering whether Sanofi’s current share price really reflects its underlying worth, or if the market is mispricing it. The stock most recently closed at €76.39, with returns of 0.8% over 7 days, a 1.6% decline over 30 days, a 7.2% decline year to date, and a 25.8% decline over the last year. These moves may have changed how investors think about both its potential and its risks. Recent coverage has focused less on short-term trading and more on Sanofi’s fundamentals and...
Is Pfizer Inc. (PFE) One of Goldman Sachs Top Healthcare Stocks?
Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target. The bullish stance follows positive phase 2 data on the company’s tri-specific antibody tilrekimig. Trial results showed that the once-a-month inhibitor achieved a placebo-adjusted high […]
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab
Cytokinetics (NASDAQ:CYTK) executives told investors at the Barclays healthcare conference that the company’s U.S. launch of MYQORZO is still in its earliest phase but showing what management described as encouraging initial signs, while a key phase 3 readout in non-obstructive hypertrophic cardiomy
Blackstone (BX) Commits $400 Million With Teva to Advance Duvakitug Clinical Development
Blackstone Inc. (NYSE:BX) is one of the 10 Best Asset Management Stocks to Buy Right Now. Top 100 Places Where the Rich People Own Real Estate On March 3, 2026, Blackstone Life Sciences, a specialized life sciences investment platform of Blackstone Inc. (NYSE:BX), entered a $400 million strategic funding agreement with Teva Pharmaceuticals. The agreement […]
Vaxart Q4 Earnings Call Highlights
Vaxart (OTCMKTS:VXRT) used its fourth-quarter business update and year-end 2025 financial results conference call to highlight a new partnership for its oral COVID-19 vaccine candidate, updates on an ongoing Phase 2b trial funded in part by the U.S. Biomedical Advanced Research and Development Autho